argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-03-09 07:17 |
argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Upda…
|
English | 23.5 KB | ||
| 2017-03-06 08:32 |
argenx announces that Staten Biotech exercised its option to develop therapeuti…
|
English | 22.6 KB | ||
| 2017-03-02 07:39 |
argenx announces intention to conduct a registered public offering in the Unite…
|
English | 33.8 KB | ||
| 2017-02-28 07:21 |
argenx to Present at Cowen & Co 37th Annual Health Care conference
|
English | 86.9 KB | ||
| 2017-02-27 08:49 |
argenx announces extension of therapeutic antibody alliance with Shire
|
English | 89.4 KB | ||
| 2017-02-09 07:38 |
argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference
|
English | 9.5 KB | ||
| 2017-01-09 08:39 |
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment o…
|
English | 90.4 KB | ||
| 2016-12-29 07:30 |
argenx announces publication of seminal data supporting the therapeutic potenti…
|
English | 22.6 KB | ||
| 2016-12-02 07:30 |
argenx to provide updates on ARGX-113 and ARGX-110 during American Society of H…
|
English | 39.8 KB | ||
| 2016-11-08 07:48 |
argenx to Present at Upcoming Investor Conferences
|
English | 122.4 KB | ||
| 2016-10-27 07:33 |
argenx Reports Third Quarter 2016 Financial Results and Provides Business Update
|
English | 43.0 KB | ||
| 2016-10-05 07:25 |
Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Hum…
|
English | 109.4 KB | ||
| 2016-09-20 14:37 | English | 1.2 MB | |||
| 2016-09-15 07:32 |
argenx to host inaugural R&D day and webcast on September 22, 2016
|
English | 59.1 KB | ||
| 2016-08-26 08:23 |
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Res…
|
English | 232.5 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
